Peripheral Artery Disease Centres of Excellence in Canada—Call to Action
Peripheral artery disease (PAD) is responsible for a significant burden of morbidity and mortality in Canada. Despite the publication of recent guidelines outlining the diagnosis and management of PAD, delivery of care continues to be fragmented. With a growing number of medical and surgical techniques available, centres of excellence are a natural evolution in the advancement of care for patients living with PAD. This article outlines current challenges and opportunities for growth to improve the care for patients with PAD in Canada.
Authors
- Darryl Wan
- Sonia Savitri Anand (ORCID: https://orcid.org/0000-0003-3692-7441)
- Eric Kaplovitch (ORCID: https://orcid.org/0000-0001-9289-6358)
- Beth L. Abramson (ORCID: https://orcid.org/0009-0008-6691-7408)
- André Roussin
- Sean Virani (ORCID: https://orcid.org/0000-0003-4481-1609)
- M. Sean McMurtry
Institutions
- St. Michael's Hospital (CA)
- Providence Health Care (CA)
- University Health Network (CA)
- University of British Columbia (CA)
- University of Alberta (CA)
- Population Health Research Institute (CA)
- Université de Montréal (CA)
Publication Details
- Journal
- Canadian Journal of Cardiology
- Published
- 2025-01-27
- DOI
- https://doi.org/10.1016/j.cjca.2025.01.019
- Citations
- 2
- Primary Topic
- Peripheral Artery Disease Management
- Type
- article
- Field-Weighted Citation Impact
- 4.01
Funders
- Amgen
- Pfizer
- Sanofi
- Novo Nordisk
- Servier
- HLS Therapeutics
- Novartis Pharmaceuticals Canada
- Janssen Pharmaceuticals
- Daiichi Sankyo Europe